Nu Skin Enterprises Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 revenue was $320.1 million with adjusted EPS of $0.20, impacted by non-cash charges. Prysm iO device placements grew nearly 30% QoQ, and the India market launch was delayed to 1H 2027 to optimize readiness. Full-year adjusted EPS guidance is $0.70–$0.90.
-
Q1 2026 results met expectations with $320.6M revenue and $0.14 adjusted EPS, driven by Prysm iO adoption and emerging market growth. Guidance for Q2 anticipates sequential improvement, while inflation and macro headwinds remain key risks.
-
The company is leveraging IoT and AI to deliver personalized wellness solutions, with Prysm iO set to drive recurring revenue and growth. Expansion in India and Latin America, along with a balanced global footprint, positions the business for long-term stability and value creation.
Fiscal Year 2025
-
Q4 and full-year 2025 results met guidance, with EPS up 51% and a 40% stock price increase. 2026 outlook anticipates growth from Prysm iO's global launch and India expansion, with revenue guidance of $1.35–$1.5 billion and EPS of $0.80–$1.20.
-
Q3 revenue and EPS met or exceeded guidance, driven by strong Latin America growth and margin improvements, while North America faced challenges. Strategic launches of Prism iO and entry into India are set to drive future growth, with profitability and innovation as ongoing priorities.
-
Q2 2025 revenue reached $386.1M with EPS of $0.43, driven by strong cost management and growth in Latin America. Guidance for 2025 was narrowed amid global uncertainties, with innovation and developing markets as key priorities.
-
Q1 2025 revenue and adjusted EPS exceeded guidance, driven by strong growth in Latin America and improving trends in key Asian and European markets, despite macroeconomic headwinds. The company reduced debt, launched new innovations, and maintained its outlook amid ongoing global uncertainties.
Fiscal Year 2024
-
Q4 revenue and adjusted EPS exceeded guidance, driven by growth in Latin America, Southeast Asia, and Rhyz, while China and South Korea remain challenging. The $250M Mavely sale strengthened the balance sheet, and 2025 guidance anticipates continued operational improvements and earnings growth.
-
Q3 results met guidance with revenue of $430.1M and EPS of $0.17, as Rhyz segments grew over 20% year-over-year while core direct selling faced ongoing declines. Operational efficiency, SKU reduction, and new sales models are key priorities, with 2024 revenue expected at $1.70–$1.73B.
-
Q2 revenue was $439.1M, with strong Rhyz growth offsetting macro headwinds and FX pressure. Guidance for 2024 was tightened, with continued focus on cost efficiency, innovation, and emerging markets. Rhyz and new product launches are key growth drivers.